Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Study of Miriplatin Hydrate (SM-11355) in Hepatocellular Carcinoma
jRCT2080220609Phase 3
- Sponsor
- Sumitomo Pharma
- Start
- Sep 2008
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of miriplatin in hepatocellular carcinoma (HCC), sponsored by Sumitomo Pharma.
02
Drugs
miriplatin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCT2080220609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220609.